Agenus (AGEN) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Agenus (AGEN) Announces Positive Efficacy Data from Glaxo (GSK) Second Shingles Vaccine Phase 3
October 27, 2015 6:56 AM EDTAgenus (NASDAQ: AGEN) announced that GlaxoSmithKlines plc (NYSE: GSK) second pivotal Phase III efficacy study of its shingles vaccine candidate containing Agenus QS-21 Stimulon® adjuvant demonstrated 90% overall efficacy against shingles compared to placebo. In this trial known as ZOE-70 (Zoster efficacy in adults aged 70 years and... More
